Patents by Inventor Wayne R. Danter

Wayne R. Danter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9284275
    Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: March 15, 2016
    Assignee: CRITICAL OUTCOME TECHNOLOGIES INC.
    Inventor: Wayne R. Danter
  • Publication number: 20150019190
    Abstract: The disclosure relates to a programmable cancer cell model that may be customized to simulate the effect of gene mutations, for example mutations identified from a particular cancer patient's tissue sample. The simulation may be used to assess the likelihood of a candidate treatment resulting in stable remission for the patient. The model makes use of a fuzzy cognitive map (FCM) simulator that employs a matrix to represent healthy cell signaling relationships and an input disease vector representing one or more genetic mutations. The disease state vector is multiplied by the matrix to produce a stable diseased cell state vector after multiple iterations. A candidate treatment may then be proposed, based upon the diseased cell state vector. After multiple iterations with a treatment vector, the efficacy of the proposed treatment on the patient's particular cancer can be assessed, reducing reliance on the traditional trial and error approach.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 15, 2015
    Inventor: Wayne R. Danter
  • Patent number: 8895556
    Abstract: The invention relates to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 25, 2014
    Assignee: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Cheuk Kun Lau
  • Patent number: 8822475
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: September 2, 2014
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Publication number: 20140072555
    Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 13, 2014
    Applicant: Critical Outcome Technologies Inc.
    Inventor: Wayne R. Danter
  • Patent number: 8580792
    Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: November 12, 2013
    Assignee: Critical Outcome Technologies Inc.
    Inventor: Wayne R. Danter
  • Publication number: 20130231345
    Abstract: The invention relates to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 5, 2013
    Applicant: CRITICAL OUTCOME TECHNOLOGIES, INC.
    Inventors: Wayne R. Danter, Cheuk Kun Lau
  • Patent number: 8466151
    Abstract: The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R5 is selected from a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or (Formula II) and the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: June 18, 2013
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R Danter, Cheuk Kun Kun Lau
  • Patent number: 8420643
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: April 16, 2013
    Assignee: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8367675
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: February 5, 2013
    Assignee: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8252800
    Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: August 28, 2012
    Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth
  • Publication number: 20120195887
    Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.
    Type: Application
    Filed: February 1, 2012
    Publication date: August 2, 2012
    Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.
    Inventor: Wayne R. Danter
  • Publication number: 20120077820
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Application
    Filed: December 2, 2011
    Publication date: March 29, 2012
    Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8138191
    Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: March 20, 2012
    Assignee: Critical Outcome Technologies Inc.
    Inventor: Wayne R. Danter
  • Publication number: 20110281887
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Application
    Filed: July 25, 2011
    Publication date: November 17, 2011
    Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8034815
    Abstract: The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: October 11, 2011
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Publication number: 20110152281
    Abstract: The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R5 is selected from a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or (Formula II) and the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.
    Type: Application
    Filed: December 24, 2008
    Publication date: June 23, 2011
    Applicant: CRITICAL OUTCOME TECHNOLOGIES, INC.
    Inventors: Wayne R. Danter, Cheuk Kun Lau
  • Publication number: 20100015140
    Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.
    Type: Application
    Filed: July 17, 2009
    Publication date: January 21, 2010
    Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.
    Inventor: Wayne R. Danter
  • Patent number: 7629347
    Abstract: The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signaling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: December 8, 2009
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R. Danter, George Ma, Natalie Lazarowych, Stephen Houldsworth, Martyn Brown, Ghenadie Rusu, Jianhua Zhong
  • Publication number: 20090298855
    Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:
    Type: Application
    Filed: July 28, 2009
    Publication date: December 3, 2009
    Applicant: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth